IS2423B - 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón - Google Patents

2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón

Info

Publication number
IS2423B
IS2423B IS7323A IS7323A IS2423B IS 2423 B IS2423 B IS 2423B IS 7323 A IS7323 A IS 7323A IS 7323 A IS7323 A IS 7323A IS 2423 B IS2423 B IS 2423B
Authority
IS
Iceland
Prior art keywords
pyrido
ylamino
pyrimidin
pyridin
Prior art date
Application number
IS7323A
Other languages
English (en)
Icelandic (is)
Other versions
IS7323A (is
Inventor
Robert Barvian Mark
John Booth Richard
Quin John Iii
Thomas Repine Joseph
James Sheehan Derek
Laurence Toogood Peter
Norman Vanderwel Scott
Zhou Hairong
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27613435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2423(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS7323A publication Critical patent/IS7323A/is
Publication of IS2423B publication Critical patent/IS2423B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
IS7323A 2002-01-22 2004-06-16 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón IS2423B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35087702P 2002-01-22 2002-01-22
PCT/IB2003/000059 WO2003062236A1 (en) 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES

Publications (2)

Publication Number Publication Date
IS7323A IS7323A (is) 2004-06-16
IS2423B true IS2423B (is) 2008-10-15

Family

ID=27613435

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7323A IS2423B (is) 2002-01-22 2004-06-16 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón

Country Status (52)

Country Link
US (4) US6936612B2 (member.php)
EP (1) EP1470124B1 (member.php)
JP (1) JP4291696B2 (member.php)
KR (2) KR20060111716A (member.php)
CN (3) CN101001857B (member.php)
AP (1) AP1767A (member.php)
AR (2) AR038814A1 (member.php)
AT (1) ATE314370T1 (member.php)
AU (1) AU2003237009B2 (member.php)
BE (1) BE2017C005I2 (member.php)
BR (2) BR122016021801B8 (member.php)
CA (1) CA2473026C (member.php)
CO (1) CO5700765A2 (member.php)
CR (1) CR20120129A (member.php)
CY (2) CY1105686T1 (member.php)
DE (1) DE60303009T2 (member.php)
DK (1) DK1470124T3 (member.php)
DO (1) DOP2003000561A (member.php)
EA (1) EA007395B3 (member.php)
EC (2) ECSP045201A (member.php)
ES (1) ES2251677T3 (member.php)
FR (1) FR17C1012I2 (member.php)
GE (1) GEP20063909B (member.php)
GT (1) GT200300005A (member.php)
HN (1) HN2003000039A (member.php)
HR (1) HRP20040660B1 (member.php)
HU (2) HUS1700009I1 (member.php)
IL (3) IL162721A0 (member.php)
IS (1) IS2423B (member.php)
LT (1) LTC1470124I2 (member.php)
LU (1) LUC00009I2 (member.php)
MA (1) MA27166A1 (member.php)
ME (1) ME00230B (member.php)
MX (1) MXPA04005939A (member.php)
MY (1) MY134818A (member.php)
NI (1) NI200300008A (member.php)
NL (1) NL300863I2 (member.php)
NO (2) NO329350B1 (member.php)
NZ (1) NZ534069A (member.php)
OA (1) OA12755A (member.php)
PA (1) PA8563701A1 (member.php)
PE (1) PE20030975A1 (member.php)
PL (2) PL218692B1 (member.php)
RS (1) RS51044B (member.php)
SI (1) SI1470124T1 (member.php)
SV (1) SV2004001459A (member.php)
TN (1) TNSN04126A1 (member.php)
TW (1) TWI343920B (member.php)
UA (1) UA79444C2 (member.php)
UY (1) UY27617A1 (member.php)
WO (1) WO2003062236A1 (member.php)
ZA (1) ZA200404840B (member.php)

Families Citing this family (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
BR0112861A (pt) * 2000-08-04 2003-07-01 Warner Lambert Co Processo para o preparo de 2-(4-piridil)amino-6-dialquilóxifenil-pirido[2,3-d]pirimi din-7-onas
ES2248233T3 (es) * 2000-08-04 2006-03-16 Warner-Lambert Company Llc Procedimiento de preparacion de 2-(4-piridil)amino-6-dialquiloxifenil-pirido(2,3-d)pirimidin-7-onas.
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
CN1503797A (zh) 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
EP1408985A4 (en) * 2001-06-21 2006-03-22 Ariad Pharma Inc NEW PYRIDOPYRIMIDONE AND ITS USES
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
JP4252534B2 (ja) 2002-08-06 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
CN1835951B (zh) 2003-07-11 2010-06-02 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
KR20060036105A (ko) * 2003-07-29 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
AU2004289428B2 (en) * 2003-11-13 2010-06-03 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PL1761528T3 (pl) * 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP5475235B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
KR101345002B1 (ko) * 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
US20080161355A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
JP5272408B2 (ja) * 2005-02-25 2013-08-28 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
AR053346A1 (es) * 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
MY153424A (en) 2005-05-10 2015-02-13 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
KR100734837B1 (ko) * 2005-09-16 2007-07-03 한국전자통신연구원 다중 생체 인식 시스템 및 그 방법
US20090221600A1 (en) * 2005-09-28 2009-09-03 Ashwani Kumar Verma Pyrido-pyridimidine derivatives useful as antiinflammatory agents
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
ES2432046T3 (es) * 2005-10-07 2013-11-29 Exelixis, Inc. Piridopirimidinonas inhibidoras de PI3Kalfa
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
AU2007297286A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
MX2009002927A (es) 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
SG184721A1 (en) 2007-10-05 2012-10-30 Genzyme Corp Method of treating polycystic kidney diseases with ceramide derivatives
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AU2009233951B2 (en) 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
ME03065B (me) 2008-07-08 2019-01-20 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
KR20130140222A (ko) * 2008-08-22 2013-12-23 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
EP2341911A4 (en) * 2008-10-01 2012-10-24 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
MX2011003517A (es) 2008-10-03 2011-05-25 Genzyme Corp Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol.
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
MY160737A (en) 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EP2474540A4 (en) * 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
PH12012500692A1 (en) * 2009-10-09 2012-11-12 Afraxis Inc 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
JP5797664B2 (ja) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8680099B2 (en) * 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
CA2807498C (en) 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
CN103936745B (zh) 2010-10-25 2017-04-12 G1治疗公司 Cdk抑制剂
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
CN103747787A (zh) 2011-05-27 2014-04-23 坦普尔大学 取代的2-亚苄基-2H-苯并[b][1,4]噻嗪-3(4H)-酮类、其衍生物及其治疗应用
CA2865167C (en) * 2012-03-14 2019-08-06 Lupin Limited Heterocyclyl compounds
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3495367B1 (en) 2012-06-13 2020-09-30 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
HRP20211218T1 (hr) 2012-07-11 2021-10-29 Blueprint Medicines Corporation Inhibitori receptora fibroblastnog faktora rasta
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2880083A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2869277T3 (es) * 2013-02-21 2021-10-25 Pfizer Formas sólidas de un inhibidor selectivo de CDK4/6
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
MX2015012741A (es) * 2013-03-15 2016-02-19 Concert Pharmaceuticals Inc Palbociclib deuterado.
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015095840A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
WO2015101293A1 (zh) 2013-12-31 2015-07-09 山东轩竹医药科技有限公司 激酶抑制剂及其用途
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
SG11201700037QA (en) 2014-07-24 2017-02-27 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
US20170217962A1 (en) * 2014-07-31 2017-08-03 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
US20170224819A1 (en) * 2014-08-11 2017-08-10 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
EP3180007A1 (en) * 2014-08-14 2017-06-21 Sun Pharmaceutical Industries Ltd Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
CN104447743B (zh) 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
EP3251672B1 (en) 2014-12-31 2023-02-01 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
TWI690533B (zh) 2015-02-12 2020-04-11 南北兄弟藥業投資有限公司 Ｃｄｋ類小分子抑制劑的化合物及其用途
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016169422A1 (zh) * 2015-04-22 2016-10-27 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN107614499B (zh) 2015-05-29 2020-09-18 帝人制药株式会社 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
CN107666914A (zh) * 2015-06-04 2018-02-06 辉瑞公司 帕博西尼的固体剂型
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
ES2741958T3 (es) 2015-08-05 2020-02-12 Ratiopharm Gmbh Nueva forma cristalina y aductos de ácido acético de palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
HK1253049A1 (zh) 2015-11-12 2019-06-06 Seagen Inc. 糖基相互作用化合物及其使用方法
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN108699055B (zh) * 2015-12-13 2020-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
WO2017114512A1 (zh) 2015-12-31 2017-07-06 上海医药集团股份有限公司 含氮稠杂环化合物、制备方法、中间体、组合物和应用
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
CN106967061A (zh) * 2016-01-13 2017-07-21 常州方楠医药技术有限公司 帕博西林的盐、晶型及其制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107266421B (zh) * 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
JP6921115B2 (ja) * 2016-04-22 2021-08-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN105949189B (zh) * 2016-06-05 2017-09-22 童明琼 一种用于治疗乳腺癌的帕博西尼的制备方法
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018007927A1 (en) 2016-07-04 2018-01-11 Dr. Reddy's Laboratories Limited Process for preparation of palbociclib
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
BR112019002610A2 (pt) 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
JP7190425B2 (ja) 2016-08-23 2022-12-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療のための併用療法
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
WO2018073687A1 (en) 2016-10-20 2018-04-26 Pfizer Inc. Anti-proliferative agents for treating pah
CN106565707B (zh) * 2016-11-03 2019-01-04 杭州科巢生物科技有限公司 帕博西尼新合成方法
EP3538148A1 (en) 2016-11-08 2019-09-18 Dana-Farber Cancer Institute Compositions and methods of modulating anti-tumor immunity
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR102290815B1 (ko) 2016-11-28 2021-08-18 데이진 화-마 가부시키가이샤 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염
CA3041854C (en) 2016-11-28 2025-05-13 Teijin Pharma Limited PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
AU2017374721B2 (en) 2016-12-16 2021-02-25 Cstone Pharmaceuticals CDK4/6 inhibitor
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
US10729692B2 (en) 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
KR102517650B1 (ko) 2017-03-16 2023-04-05 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암의 치료를 위한 조합물 요법
CN108658855A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种含氮双环化合物及其制备方法和用途
CN108658854A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种生物碱化合物及其制备方法和作为海洋防污剂的应用
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201904577A (zh) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
EA036060B1 (ru) * 2017-07-17 2020-09-21 Пфайзер Инк. Пиридопиримидиноновые ингибиторы cdk2/4/6
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
CN119193825A (zh) 2017-08-31 2024-12-27 诺华股份有限公司 选择针对癌症患者的治疗的方法
CN107488175A (zh) * 2017-09-04 2017-12-19 上海微巨实业有限公司 一种帕博西林关键中间体的制备方法
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
SG11202006748RA (en) 2018-01-29 2020-08-28 Beta Pharma Inc 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CR20230030A (es) 2018-02-27 2023-03-10 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
SMT202400507T1 (it) 2018-05-04 2025-01-14 Incyte Corp Forme solide di un inibitore di fgfr e procedimenti per preparare le stesse
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
EP4309656A3 (en) 2018-05-14 2024-02-28 Pfizer Inc. Oral solution formulation
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
WO2019224194A1 (en) 2018-05-24 2019-11-28 Synthon B.V. A process for making palbociclib
UA128332C2 (uk) 2018-07-05 2024-06-12 Інсайт Корпорейшн Похідні конденсованих піразинів як інгібітори a2a/a2b
TW202430189A (zh) 2018-07-23 2024-08-01 瑞士商赫孚孟拉羅股份公司 用pi3k抑制劑gdc-0077治療癌症之方法
BR112021001499A2 (pt) 2018-07-27 2021-04-27 California Institute Of Technology inibidores de cdk e usos dos mesmos
SG11202101807SA (en) 2018-08-24 2021-03-30 G1 Therapeutics Inc Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12358911B2 (en) 2018-12-07 2025-07-15 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
EP3902801A4 (en) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
SG11202108702XA (en) * 2019-02-15 2021-09-29 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3976043A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
CN112010844B (zh) * 2019-05-31 2023-07-25 中国药科大学 N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN113993505B (zh) * 2019-06-20 2023-12-12 江苏恒瑞医药股份有限公司 一种药物组合物以及其制备方法
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
WO2021007146A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ｉｄｏ阻害剤の投与レジメン
EP4013750A1 (en) 2019-08-14 2022-06-22 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
WO2021113219A1 (en) 2019-12-03 2021-06-10 Genentech, Inc. Combination therapies for treatment of breast cancer
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
JP7657222B2 (ja) * 2019-12-16 2025-04-04 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
BR112022011758A2 (pt) 2019-12-16 2022-08-30 Lunella Biotech Inc Terapêutica de câncer inibidor de cdk4/6 seletivo
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
US12214036B2 (en) 2020-03-06 2025-02-04 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
WO2021183994A1 (en) * 2020-03-13 2021-09-16 Prosenestar Llc Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
WO2021190637A1 (en) * 2020-03-27 2021-09-30 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
EP4135844A1 (en) 2020-04-16 2023-02-22 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
IL298294B1 (en) 2020-05-19 2025-11-01 G1 Therapeutics Inc Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2021242770A1 (en) * 2020-05-28 2021-12-02 University Of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113880809B (zh) 2020-07-03 2022-10-18 盛世泰科生物医药技术(苏州)有限公司 一种嘧啶类衍生物及其制备方法和应用
TW202216131A (zh) 2020-07-15 2022-05-01 美商輝瑞大藥廠 用於癌症治療之ｋａｔ６抑制劑方法及組合
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
CN114246841B (zh) * 2020-09-24 2024-02-02 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112569361B (zh) * 2020-12-30 2023-01-10 扬子江药业集团上海海尼药业有限公司 一种哌柏西利干混悬组合物及其制备方法
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US12428420B2 (en) 2021-06-09 2025-09-30 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
EP4353724A4 (en) * 2021-06-09 2025-10-08 Tyk Medicines Zhengzhou Inc COMPOUND USEFUL AS A CYCLIN-DEPENDENT KINASE INHIBITOR AND USE THEREOF
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
TW202317565A (zh) 2021-07-07 2023-05-01 美商英塞特公司 作為kras抑制劑的三環化合物
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
AU2022320615B2 (en) 2021-07-26 2025-08-21 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
CN113683612B (zh) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 一种帕布昔利布的制备方法
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
IL313422A (en) 2021-12-10 2024-08-01 Lilly Co Eli CDK4 and 6 inhibitor in combination with FULVESTRANT for the treatment of advanced or metastatic breast cancer in patients with advanced or metastatic breast cancer before CDK 4 and 4
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
US20230192722A1 (en) 2021-12-22 2023-06-22 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
JP2025512710A (ja) 2022-03-07 2025-04-22 インサイト・コーポレイション Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
HU231594B1 (hu) * 2022-05-10 2025-03-28 Egis Gyógyszergyár Zrt. Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
JP2025530742A (ja) 2022-08-31 2025-09-17 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質の投与計画
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
TW202440571A (zh) * 2022-12-16 2024-10-16 大陸商上海岸闊醫藥科技有限公司 化合物及其用途
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
TW202446371A (zh) 2023-04-18 2024-12-01 美商英塞特公司 ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
AU2024269592A1 (en) 2023-05-05 2025-12-18 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
US20250177414A1 (en) 2023-12-04 2025-06-05 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618982A (en) 1979-06-14 1981-02-23 Wellcome Found Pyrimidine derivatives and medicinal drug containing them
US4959474A (en) 1979-06-14 1990-09-25 Burroughs Wellcome Co. Dialkoxy pyridopyrimidine compounds
IL60307A (en) 1979-06-14 1984-02-29 Wellcome Found 2,4-diamino-6-(dimethoxybenzyl)-5-methylpyrido-(2,3-d)pyrimidines,their preparation and pharmaceutical compositions containing them
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
ATE159009T1 (de) 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
CA2250943A1 (en) 1996-04-12 1997-10-23 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
SK5212000A3 (en) 1997-10-27 2001-04-09 Agouron Pharmaceuticals Inc Ag 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
PL344248A1 (en) * 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
ES2251395T3 (es) 1999-07-26 2006-05-01 Banyu Pharmaceutical Co., Ltd. Derivados de biarilureas.
JP2003509425A (ja) 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
CZ20022521A3 (cs) * 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění
BR0109056A (pt) * 2000-03-06 2003-06-03 Warner Lambert Co Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
ATE408613T1 (de) 2000-08-04 2008-10-15 Warner Lambert Co 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3- d)pyrimidin-7-one
AU2001271611A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Oxindole derivatives
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
EP1463730B1 (en) 2001-12-17 2006-04-19 SmithKline Beecham Corporation Pyrazolopyridazine derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US7189712B2 (en) 2002-10-10 2007-03-13 Smithkline Beecham Corporation 1,3-Oxazole compounds for the treatment of cancer
KR20050085115A (ko) 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
US20050009849A1 (en) * 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
DE602004016964D1 (de) 2003-02-27 2008-11-20 Smithkline Beecham Corp Neue verbindungen
CN1835951B (zh) 2003-07-11 2010-06-02 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
AU2007297286A1 (en) 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

Also Published As

Publication number Publication date
RS59804A (sr) 2006-12-15
US20070179118A1 (en) 2007-08-02
US20030149001A1 (en) 2003-08-07
BRPI0307057B1 (pt) 2018-05-29
JP2005519909A (ja) 2005-07-07
NO20043484L (no) 2004-10-15
NO329350B1 (no) 2010-10-04
IS7323A (is) 2004-06-16
BR122016021801B8 (pt) 2021-05-25
ZA200404840B (en) 2005-09-28
GT200300005A (es) 2003-08-22
CR20120129A (es) 2012-06-12
HK1162026A1 (en) 2012-08-17
WO2003062236A8 (en) 2003-12-24
ECSP105201A (es) 2010-02-26
GEP20063909B (en) 2006-08-25
CN102295643B (zh) 2013-12-04
ATE314370T1 (de) 2006-01-15
CY2017011I2 (el) 2017-11-14
KR20060111716A (ko) 2006-10-27
UA79444C2 (uk) 2007-06-25
AP2004003085A0 (en) 2004-09-30
MEP46108A (en) 2011-02-10
DK1470124T3 (da) 2006-04-18
CN101001857A (zh) 2007-07-18
USRE47739E1 (en) 2019-11-26
SI1470124T1 (sl) 2006-04-30
RS51044B (sr) 2010-10-31
NO2017014I2 (no) 2017-04-19
MXPA04005939A (es) 2005-01-25
DE60303009D1 (de) 2006-02-02
EA007395B1 (ru) 2006-10-27
US20050137214A1 (en) 2005-06-23
EA007395B3 (ru) 2018-02-28
CN102295643A (zh) 2011-12-28
OA12755A (en) 2006-07-03
HUS1700019I1 (hu) 2017-05-29
TNSN04126A1 (fr) 2007-03-12
IL162721A (en) 2009-12-24
EP1470124A1 (en) 2004-10-27
FR17C1012I1 (member.php) 2017-07-07
HK1146048A1 (en) 2011-05-13
LUC00009I2 (member.php) 2017-05-30
HK1104296A1 (en) 2008-01-11
PL372046A1 (en) 2005-07-11
US7456168B2 (en) 2008-11-25
AP1767A (en) 2007-08-13
CN101001857B (zh) 2011-06-22
AU2003237009B2 (en) 2008-10-02
LTPA2017013I1 (lt) 2017-05-25
HRP20040660B1 (hr) 2012-10-31
PL220952B1 (pl) 2016-01-29
TW200302224A (en) 2003-08-01
CY2017011I1 (el) 2017-11-14
CA2473026A1 (en) 2003-07-31
BRPI0307057B8 (pt) 2021-05-25
CO5700765A2 (es) 2006-11-30
EP1470124B1 (en) 2005-12-28
UY27617A1 (es) 2003-08-29
PL391191A1 (member.php) 2005-07-11
AR038814A1 (es) 2005-01-26
ES2251677T3 (es) 2006-05-01
PE20030975A1 (es) 2003-11-12
NO2017014I1 (no) 2017-04-19
CY1105686T1 (el) 2010-12-22
TWI343920B (en) 2011-06-21
US6936612B2 (en) 2005-08-30
LTC1470124I2 (lt) 2019-04-25
FR17C1012I2 (fr) 2018-06-08
CN101906104A (zh) 2010-12-08
IL198243A (en) 2013-05-30
MA27166A1 (fr) 2005-01-03
SV2004001459A (es) 2004-07-07
CN101906104B (zh) 2013-06-05
IL162721A0 (en) 2005-11-20
HN2003000039A (es) 2005-11-12
BR0307057A (pt) 2004-10-26
ME00230B (me) 2011-02-10
KR100669578B1 (ko) 2007-01-15
US7208489B2 (en) 2007-04-24
MY134818A (en) 2007-12-31
DOP2003000561A (es) 2003-09-15
BE2017C005I2 (member.php) 2022-05-17
EA200400860A1 (ru) 2004-12-30
HUS1700009I1 (hu) 2017-07-28
ECSP045201A (es) 2004-08-27
DE60303009T2 (de) 2006-07-13
WO2003062236A1 (en) 2003-07-31
LUC00009I1 (member.php) 2017-03-16
NI200300008A (es) 2004-12-03
JP4291696B2 (ja) 2009-07-08
KR20040077759A (ko) 2004-09-06
NZ534069A (en) 2007-03-30
PL218692B1 (pl) 2015-01-30
PA8563701A1 (es) 2003-09-17
NL300863I2 (nl) 2017-08-03
CA2473026C (en) 2011-05-03
HRP20040660A2 (en) 2004-12-31
AR083686A2 (es) 2013-03-13
BR122016021801B1 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
IS2423B (is) 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
DE60135854D1 (de) 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-one
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
ATE284404T1 (de) Pyrazolo(4,3-d)pyrimidinderivate
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ATE433977T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate
AU2003255323A8 (en) Imidazo`1,2-a pyridines
NO20043565L (no) Heteroaryl-substituerte 2-pyridinyl- og 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater.
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner